Maintenance therapy in epithelial ovarian cancer: From chemotherapy to targeted agents

Cristina Falci, Maria Vittoria Dieci, Valentina Guarneri, Caterina Soldà, Emilio Bria, Giampaolo Tortora, Pierfranco Conte

Research output: Contribution to journalArticlepeer-review


Over the past years, although no increase in the cure rate for advanced epithelial ovarian cancer patients has been achieved, a slow prolongation in patients survival has been observed, thanks to the introduction of effective second line or salvage therapies. Attempts to disease chronicization seem therefore of value in this setting. A major effort has been pursued to establish the role of maintenance therapies for epithelial ovarian cancer patients. Although chemotherapy does not seem to have an effective role, promising results are coming from trials investigating maintenance targeted treatments, especially with antiangiogenic agents or PARP inhibitors for selected patients. The aim of this article is to review current evidences on maintenance therapy for epithelial ovarian cancer and put the results in perspective.

Original languageEnglish
Pages (from-to)1041-1050
Number of pages10
JournalExpert Review of Anticancer Therapy
Issue number9
Publication statusPublished - 2014


  • antiangiogenic agent
  • epithelial ovarian cancer
  • maintenance

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology
  • Medicine(all)


Dive into the research topics of 'Maintenance therapy in epithelial ovarian cancer: From chemotherapy to targeted agents'. Together they form a unique fingerprint.

Cite this